# Protein Kinase D2 Regulates GRASP65 Phosphorylation and Golgi Ribbon Unlinking During G2/M Transition

**Authors:** Inmaculada Ayala, Daniela Spano, Antonino Colanzi

PMC · DOI: 10.3390/cells15060565 · Cells · 2026-03-21

## TL;DR

This study shows that PKD2 regulates GRASP65 phosphorylation, which is essential for Golgi ribbon unlinking during the G2/M transition in the cell cycle.

## Contribution

The study identifies PKD2 as a novel upstream regulator of GRASP65 phosphorylation and introduces a new phospho-specific antibody for studying Golgi dynamics.

## Key findings

- PKD2 activity is required for JNK2-dependent phosphorylation of GRASP65 at S274 during G2.
- PKD2 inhibition reduces GRASP65 phosphorylation and Golgi ribbon unlinking, delaying G2/M progression.
- A PKD2–JNK2–GRASP65 signaling axis controls Golgi disassembly at the G2/M transition.

## Abstract

What are the main findings?
PKD2 is an upstream regulator of JNK2-dependent GRASP65 phosphorylation at serine 274 during the G2 phase.PKD2 activity is required for Golgi ribbon unlinking and proper G2/M progression.

PKD2 is an upstream regulator of JNK2-dependent GRASP65 phosphorylation at serine 274 during the G2 phase.

PKD2 activity is required for Golgi ribbon unlinking and proper G2/M progression.

What are the implications of the main findings?
A PKD2–JNK2–GRASP65 signaling axis links Golgi remodeling to mitotic entry.The newly developed phospho-specific GRASP65 antibody enables investigation of upstream Golgi regulatory pathways in cell cycle control and disease.

A PKD2–JNK2–GRASP65 signaling axis links Golgi remodeling to mitotic entry.

The newly developed phospho-specific GRASP65 antibody enables investigation of upstream Golgi regulatory pathways in cell cycle control and disease.

The Golgi complex undergoes dynamic remodeling during the cell cycle, as ribbon unlinking in G2 is required for proper mitotic progression. Failure to fragment the ribbon leads to G2 arrest, whereas forced mitotic entry with intact ribbons results in multipolar spindle formation. Phosphorylation of the Golgi matrix protein GRASP65 at serine 277 (S277) in rat (S274 in human) by JNK2 is essential for ribbon unlinking, but its upstream regulation has remained unclear. Here, we generated and validated a phospho-specific antibody recognizing human GRASP65 phosphorylated at S274, enabling accurate detection of this modification. Using this tool, we identify protein kinase D2 (PKD2) as a critical upstream regulator required for GRASP65 phosphorylation and Golgi unlinking. GRASP65-S274 phosphorylation increases during G2 and is markedly reduced upon PKD2 inhibition or depletion, resulting in decreased Golgi unlinking and delayed G2/M transition. Conversely, PKD2-activating stimuli, including phorbol esters and nocodazole, enhance GRASP65 phosphorylation in a PKD2-dependent manner. These findings define PKD2 as a key regulator of the JNK2–GRASP65 signaling axis controlling Golgi disassembly at the G2/M transition. Moreover, the phospho-specific GRASP65 antibody described here provides a valuable tool to dissect upstream signaling mechanisms and to identify the initial triggers driving Golgi unlinking at G2 entry.

## Linked entities

- **Genes:** PKD2 (polycystin 2, transient receptor potential cation channel) [NCBI Gene 5311], MAPK9 (mitogen-activated protein kinase 9) [NCBI Gene 5601], GORASP1 (golgi reassembly stacking protein 1) [NCBI Gene 64689]
- **Proteins:** GORASP1 (golgi reassembly stacking protein 1), PKD2 (polycystin 2, transient receptor potential cation channel), MAPK9 (mitogen-activated protein kinase 9)

## Full-text entities

- **Genes:** PRKD1 (protein kinase D1) [NCBI Gene 5587] {aka CHDED, PKC-MU, PKCM, PKD, PKD1, PRKCM}, TAMALIN (trafficking regulator and scaffold protein tamalin) [NCBI Gene 160622] {aka GRASP}, CDC42 (cell division cycle 42) [NCBI Gene 998] {aka CDC42Hs, G25K, TKS}, MAP2K4 (mitogen-activated protein kinase kinase 4) [NCBI Gene 6416] {aka JNKK, JNKK1, MAPKK4, MEK4, MKK4, PRKMK4}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, RAC1 (Rac family small GTPase 1) [NCBI Gene 5879] {aka MIG5, MRD48, Rac-1, TC-25, p21-Rac1}, APCS (amyloid P component, serum) [NCBI Gene 325] {aka HEL-S-92n, PTX2, SAP}, CXCR6 (C-X-C motif chemokine receptor 6) [NCBI Gene 10663] {aka BONZO, CD186, CDw186, STRL33, TYMSTR}, GORASP1 (golgi reassembly stacking protein 1) [NCBI Gene 64689] {aka GOLPH5, GRASP65, P65}, CDK1 (cyclin dependent kinase 1) [NCBI Gene 983] {aka CDC2, CDC28A, P34CDC2}, ARHGEF2 (Rho/Rac guanine nucleotide exchange factor 2) [NCBI Gene 9181] {aka GEF, GEF-H1, GEFH1, LFP40, Lfc, NEDMHM}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, MAPK9 (mitogen-activated protein kinase 9) [NCBI Gene 5601] {aka JNK-55, JNK2, JNK2A, JNK2ALPHA, JNK2B, JNK2BETA}, GOLGA2 (golgin A2) [NCBI Gene 2801] {aka DEDHMB, GM130}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, PRKD2 (protein kinase D2) [NCBI Gene 25865] {aka HSPC187, PKD2, nPKC-D2}, PKD2 (polycystin 2, transient receptor potential cation channel) [NCBI Gene 5311] {aka APKD2, PC2, PKD4, Pc-2, TRPP2}, PLK1 (polo like kinase 1) [NCBI Gene 5347] {aka PLK, STPK13}, VN1R17P (vomeronasal 1 receptor 17 pseudogene) [NCBI Gene 441931] {aka GPCR}, MAP3K12 (mitogen-activated protein kinase kinase kinase 12) [NCBI Gene 7786] {aka DLK, HP09298, MEKK12, MUK, ZPK, ZPKP1}, GORASP2 (golgi reassembly stacking protein 2) [NCBI Gene 26003] {aka GOLPH6, GRASP55, GRS2, p59}, RAB6A (RAB6A, member RAS oncogene family) [NCBI Gene 5870] {aka RAB6}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, DEPDC1B (DEP domain containing 1B) [NCBI Gene 55789] {aka BRCC3, XTP1}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, MAP2K1 (mitogen-activated protein kinase kinase 1) [NCBI Gene 5604] {aka CFC3, MAPKK1, MEK1, MEL, MKK1, PRKMK1}, PTPRF (protein tyrosine phosphatase receptor type F) [NCBI Gene 5792] {aka BNAH2, LAR}, PKD1 (polycystin 1, transient receptor potential channel interacting) [NCBI Gene 5310] {aka PBP, PC1, Pc-1, TRPP1, eliosin}, PI4KB (phosphatidylinositol 4-kinase beta) [NCBI Gene 5298] {aka DFNA87, NPIK, PI4K-BETA, PI4K92, PI4KBETA, PI4KIII}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, GOLGA3 (golgin A3) [NCBI Gene 2802] {aka GCP170, MEA-2}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, CERT1 (ceramide transporter 1) [NCBI Gene 10087] {aka CERT, CERTL, COL4A3BP, GPBP, MRD34, NEDHSF}, ARF1 (ARF GTPase 1) [NCBI Gene 375] {aka PVNH8}, AURKA (aurora kinase A) [NCBI Gene 6790] {aka AIK, ARK1, AURA, BTAK, PPP1R47, STK15}, PRRT2 (proline rich transmembrane protein 2) [NCBI Gene 112476] {aka BFIC2, BFIS2, DSPB3, DYT10, EKD1, FICCA}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, PCNT (pericentrin) [NCBI Gene 5116] {aka KEN, MOPD2, PCN, PCNT2, PCNTB, PCTN2}, SRC (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 6714] {aka ASV, SRC1, THC6, c-SRC, p60-Src}, PLCB3 (phospholipase C beta 3) [NCBI Gene 5331] {aka SMDCD}, RAF1 (Raf-1 proto-oncogene, serine/threonine kinase) [NCBI Gene 5894] {aka CMD1NN, CRAF, NS5, Raf-1, c-Raf}, RHOA (ras homolog family member A) [NCBI Gene 387] {aka ARH12, ARHA, EDFAOB, RHO12, RHOH12}, PKD3 [NCBI Gene 5312], DAPK1 (death associated protein kinase 1) [NCBI Gene 1612] {aka DAPK, ROCO3}, BLZF1 (basic leucine zipper nuclear factor 1) [NCBI Gene 8548] {aka GOLGIN-45, JEM-1, JEM-1s, JEM1}, MAP3K11 (mitogen-activated protein kinase kinase kinase 11) [NCBI Gene 4296] {aka MEKK11, MLK-3, MLK3, PTK1, SPRK}
- **Diseases:** injury to (MESH:D014947), tumorigenesis (MESH:D063646), GC (MESH:D048090), viral infection (MESH:D014777), cancer (MESH:D009369)
- **Chemicals:** phorbol esters (MESH:D010703), UO126 (MESH:C113580), DMEM (-), streptomycin (MESH:D013307), EGTA (MESH:D004533), Lipofectamine (MESH:C086724), L-glutamine (MESH:D005973), beta-glycerol phosphate (MESH:C031463), SP600125 (MESH:C432165), paraformaldehyde (MESH:C003043), Thymidine (MESH:D013936), SDS (MESH:D012967), PD98059 (MESH:C093973), lipid (MESH:D008055), PMA (MESH:D013755), EDTA (MESH:D004492), PI4P (MESH:C037178), glycerol (MESH:D005990), Alexa Fluor 488 (MESH:C000711379), TX-100 (MESH:C551282), saponin (MESH:D012503), Dasatinib (MESH:D000069439), NZ (MESH:D015739), PBS (MESH:D007854), NaF (MESH:D012969), DAG (MESH:D004075), DMSO (MESH:D004121), penicillin (MESH:D010406), RO-3306 (MESH:C512984), CO2 (MESH:D002245), CRT0066101 (MESH:C551536), Hoechst 33342 (MESH:C017807), NaCl (MESH:D012965), NH4Cl (MESH:D000643)
- **Species:** Toxoplasma gondii (species) [taxon 5811], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Drosophila melanogaster (fruit fly, species) [taxon 7227], Rattus norvegicus (brown rat, species) [taxon 10116], Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932]
- **Mutations:** serine/threonine, S274
- **Cell lines:** HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030), S2 — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z232)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13025926/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13025926/full.md

## References

96 references — full list in the complete paper: https://tomesphere.com/paper/PMC13025926/full.md

---
Source: https://tomesphere.com/paper/PMC13025926